CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Concurrent Ibrutinib With CAR T-Cell Therapy Improves ORR, Reduces Severe CRS in High-Risk CLL

June 22nd 2019

Patients with high-risk relapsed/refractory chronic lymphocytic leukemia who failed or were intolerant of ibrutinib derived more benefit from CD19‐targeted CAR T-cell therapy when the BTK inhibitor was concurrently administered than when it was not.

Dr. Siddiqi on CAR T-Cell Therapy in Relapsed/Refractory CLL/SLL

June 21st 2019

Tanya Siddiqi, MD, a hematologist/oncologist at City of Hope, discusses the phase I/II TRANSCEND CLL 004 trial, which evaluated the efficacy of anti-CD19 CAR T cells in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Lisocabtagene Maraleucel Continues to Show Promise in Relapsed/Refractory CLL

June 21st 2019

The CAR T-cell therapy lisocabtagene maraleucel demonstrated high rates of response, including minimum residual disease in blood and marrow in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr. Shadman on Next Steps for CAR T-Cell Therapy in DLBCL

June 11th 2019

Mazyar Shadman, MD, MPH, assistant member, Fred Hutchinson Cancer Research Center, discusses next steps for CAR T-cell therapy in diffuse large B-cell lymphoma.

Expert Excited for Next Steps With CAR-T in Non-Hodgkin Lymphoma

June 10th 2019

Ahmed Galal, MD, sheds light on the current use of CAR T-cell therapy in relapsed/refractory lymphomas and a handful of strategies to expand the reach of this therapy.

Dr. Maziarz on Unanswered Questions With CAR T-Cell Therapy in DLBCL

June 4th 2019

Richard T. Maziarz, MD, professor of medicine at Oregon Health & Science University, Knight Cancer Institute, discusses unanswered questions with CAR T-cell therapy in diffuse large B-cell lymphoma.

Dr. Goy on CAR T-Cell Therapy Updates in Non-Hodgkin Lymphoma

June 1st 2019

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses updates in CAR T-cell therapy that are being presented at the 2019 ASCO Annual Meeting.

Dr. Shah on Differences Between Anti-CD19 CAR T-Cell Therapies

May 30th 2019

Nirav N. Shah, MD, assistant professor, Medical College of Wisconsin, discusses the differences between anti–CD19 CAR T-cell therapies.

Targeting Mesothelin May Yield Results in Hard-to-Treat Solid Tumors

May 22nd 2019

Mesothelin, a protein found on cell surfaces and in serum, has emerged as a promising target for immunotherapy-based treatment approaches for several malignancies with poor prognoses and limited treatment options. Investigating novel approaches to optimize delivery and identifying combinations of agents to synergistically improve therapeutic response will be the next steps in bringing mesothelin-targeted therapies into the clinical setting.

Dr. Galal on CAR T-Cell Therapy in Relapsed/Refractory Lymphomas

May 15th 2019

Ahmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses the use of CAR T-cell therapy in patients with relapsed/refractory lymphomas.

FDA Grants P-BCMA-101 CAR T-Cell Therapy Orphan Drug Designation for Myeloma

May 14th 2019

The FDA has granted an orphan drug designation to the autologous CAR T-cell therapy P-BCMA-101 for the treatment of patients with relapsed/refractory multiple myeloma.

Dr. Lekakis on Managing the Toxicity of CAR T-Cell Therapy

May 13th 2019

Lazaros John Lekakis, MD, associate professor of clinical medicine, Sylvester Comprehensive Cancer Center, University of Miami, discusses managing the toxicity of CAR T-cell therapy.

Early Trials Suggest New Path for CAR T-Cell Therapy in Solid Tumors

May 10th 2019

Two novel CAR T-cell therapies designed to attack solid tumors are showing signs of antitumor activity and tolerability in early clinical trial findings, fueling optimism about expanding this emerging form of immunotherapy beyond hematologic malignancies.

Dr. Duncan on the Expansion of CAR T-Cell Therapy

May 9th 2019

Christine N. Duncan, MD, a senior physician at Dana-Farber Cancer Institute, and assistant professor of pediatrics, Harvard Medical School, discusses the expansion of CAR T-cell therapy in oncology.

Future Looks Bright for CAR T-Cell Therapies in Hematologic Malignancies

May 8th 2019

Nirav N. Shah, MD, discusses the promise of CAR T-cell therapy in hematologic malignancies and highlights recent research exploring sequential CAR-T therapies, armored CAR T cells, as well as other novel approaches.

Dr. Galal on Ways of Extending the Reach of CAR T-Cell Therapy

May 7th 2019

Ahmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses ways of extending the reach of CAR T-cell therapy in real-world practice.

Dr. Shah Discusses Ongoing Research With CAR T-Cell Therapy

May 2nd 2019

Nirav N. Shah, MD, assistant professor, Medical College of Wisconsin, discusses ongoing research with CAR T-cell therapy.

Research Propels Forward With CAR T-Cell Therapy in Pediatric ALL

April 28th 2019

Christine N. Duncan, MD, discusses the current components of CAR T-cell therapy in pediatric acute lymphoblastic leukemia.

Dr. Duncan on the Use of CAR T-Cell Therapy in Pediatric ALL

April 19th 2019

Christine N. Duncan, MD, senior physician, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses the use of CAR T-cell therapy in the treatment of pediatric patients with acute lymphocytic leukemia (ALL).

Mesothelin-Targeted CAR T Cells Show Early Promise in Solid Tumors

April 12th 2019

Prasad S. Adusumilli, MD, sheds light on the preliminary phase I data from a trial of CAR T-cell therapy in malignant pleural disease from mesothelioma.